155 related articles for article (PubMed ID: 19760609)
21. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors.
Perotti D; Gamba B; Sardella M; Spreafico F; Terenziani M; Collini P; Pession A; Nantron M; Fossati-Bellani F; Radice P
Oncogene; 2008 Jul; 27(33):4625-32. PubMed ID: 18391980
[TBL] [Abstract][Full Text] [Related]
22. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
23. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
24. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.
Akhavanfard S; Vargas SO; Han M; Nitta M; Chang CB; Le LP; Fazlollahi L; Nguyen Q; Ma Y; Cosper A; Dias-Santagata D; Han JY; Bergethon K; Borger DR; Ellisen LW; Pomeroy SL; Haber DA; Iafrate AJ; Rivera MN
Genes Chromosomes Cancer; 2014 Jan; 53(1):67-77. PubMed ID: 24249259
[TBL] [Abstract][Full Text] [Related]
26. Clinical, Pathologic, and Genetic Features of Wilms Tumors With WTX Gene Mutation.
Alexandrescu S; Akhavanfard S; Harris MH; Vargas SO
Pediatr Dev Pathol; 2017; 20(2):105-111. PubMed ID: 28326956
[TBL] [Abstract][Full Text] [Related]
27. Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor.
Cao X; Liu D; Yan X; Zhang Y; Yuan L; Zhang T; Fu M; Zhou Y; Wang J
FEBS Lett; 2013 Mar; 587(6):639-44. PubMed ID: 23333300
[TBL] [Abstract][Full Text] [Related]
28. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
29. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
30. Mutational analysis of WTX gene in Wnt/ beta-catenin pathway in gastric, colorectal, and hepatocellular carcinomas.
Yoo NJ; Kim S; Lee SH
Dig Dis Sci; 2009 May; 54(5):1011-4. PubMed ID: 18720004
[TBL] [Abstract][Full Text] [Related]
31. Wilms tumor genetics: a new, UnX-pected twist to the story.
Huff V
Cancer Cell; 2007 Feb; 11(2):105-7. PubMed ID: 17292822
[TBL] [Abstract][Full Text] [Related]
32. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
[TBL] [Abstract][Full Text] [Related]
33. Is predisposition for nephroblastoma linked to polymorphisms of the WTX gene?
Guertl B; Leuschner I; Guelly C; Ebner B; Kronberger C; Hoefler G
Pathol Oncol Res; 2010 Jun; 16(2):189-91. PubMed ID: 19757195
[TBL] [Abstract][Full Text] [Related]
34. [The tumor suppressor gene WTX, mutated in Wilms tumours, is a member of the beta-catenin destruction complex].
Angers S
Med Sci (Paris); 2007 Nov; 23(11):1025-7. PubMed ID: 18021721
[No Abstract] [Full Text] [Related]
35. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
36. Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.
Kim MK; Min DJ; Rabin M; Licht JD
Oncogene; 2011 Feb; 30(7):832-42. PubMed ID: 20956941
[TBL] [Abstract][Full Text] [Related]
37. Bilateral Wilms tumor and early presentation in pediatric patients is associated with the truncation of the Wilms tumor 1 protein.
Hu M; Fletcher J; McCahon E; Catchpoole D; Zhang GY; Wang YM; Algar EM; Alexander SI
J Pediatr; 2013 Jul; 163(1):224-9. PubMed ID: 23403252
[TBL] [Abstract][Full Text] [Related]
38. Is WTX a suitable target for cancer therapy?
Perotti D; Radice P
Pediatr Blood Cancer; 2011 Apr; 56(4):682. PubMed ID: 21298763
[No Abstract] [Full Text] [Related]
39. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
40. Molecular evidence of the independent origin of multiple Wilms tumors in a case of WAGR syndrome.
Uccini S; Perotti D; Colarossi C; Stoppacciaro A; Sardella M; Mannarino O; Collini P; Casieri P; Cozzi D; Amoroso L; Spreafico F; Radice P; Dominici C
Pediatr Blood Cancer; 2008 Sep; 51(3):344-8. PubMed ID: 18293378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
